Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 90   

Articles published

PSTI 0.800 -0.040 (-4.76%)
price chart
Price Target Update On Pluristem Therapeutics, Inc. (PSTI)
A number of investment brokers have recently updated their price targets on shares of Pluristem Therapeutics, Inc. (PSTI).
Pluristem Therapeutics Says PIM 160 LTE MIMO Antenna Gets Specific ...  WallStreet.org
Pluristem Therapeutics Inc. (PSTI) Upgraded at Zacks Investment Research  Intercooler Financial
Pluristem Therapeutics Inc. (PSTI) Rating Reiterated by Zacks Investment Research
Pluristem Therapeutics logo Pluristem Therapeutics Inc. (NASDAQ:PSTI)'s stock had its “hold” rating restated by Zacks Investment Research in a report released on Sunday, MarketBeat.
5% Stake of Pluristem Therapeutics Inc. (PSTI) Held by Sabby Healthcare ...  Corvus Business Newswire
Pluristem Therapeutics Inc. (PSTI) Sees Large Decline in Short Interest  Intercooler Financial
Pluristem Therapeutics Inc. (PSTI) Given "Buy" Rating at Maxim Group
Pluristem Therapeutics logo Pluristem Therapeutics Inc. (NASDAQ:PSTI)'s stock had its “buy” rating reaffirmed by investment analysts at Maxim Group in a research note issued to investors on Tuesday, MarketBeat Ratings reports.
5% Stake of Pluristem Therapeutics Inc. (PSTI) Maintained by Sabby ...  Zolmax
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Receives $4.00 Consensus Price ...
Pluristem Therapeutics logo Pluristem Therapeutics Inc. (NASDAQ:PSTI) has earned an average rating of “Buy” from the six research firms that are covering the company, Market Beat.
Pluristem Therapeutics' (PSTI) "Buy" Rating Reaffirmed at ...  Corvus Business Newswire
Zacks Investment Research Reiterates Buy Rating for Pluristem Therapeutics ...  Zolmax
Pluristem Therapeutics Inc. (NASDAQ:PSTI) Receives Average Rating of "Buy ...
Pluristem Therapeutics logo Pluristem Therapeutics Inc. (NASDAQ:PSTI) has received an average rating of “Buy” from the six analysts that are currently covering the company, MarketBeat.
Pluristem Therapeutics' (PSTI) Buy Rating Reiterated at Maxim Group  Intercooler Financial
Pluristem Therapeutics Inc.Pipeline Review, Market Share, Stragegy, Size and ...
MRS66 “Pluristem Therapeutics Inc.Pipeline Review, H2 2015“, provides an overview of the Pluristem Therapeutics Inc. 's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Pluristem Therapeutics Inc., ...
Maxim Group Maintains Buy on Pluristem Therapeutics Inc. Following Patent Issuance
In a research report released Monday, Maxim Group analyst Jason Kolbert maintained a Buy rating on shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) with an $8.00 price target, after the company announced that the U.S Patent and Trademark Office ...
MLV Offers Commentary on Pluristem Therapeutics Inc. Following Regulatory Updates
In a research report released today, MLV's healthcare analyst Vernon Bernardino reiterated a Buy rating on shares of Pluristem Therapeutics Inc (NASDAQ:PSTI), with a $6 price target, after the company announced that the Japan's Pharmaceuticals and ...
Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in ...  GlobeNewswire (press release)
Pluristem Therapeutics Skyrockets After FDA Approval
Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced that the Food and Drug Administration (FDA) has approved PLX-PAD cells Orphan Drug Administration (ODD), which treats severe preeclampsia.
Shares Of Pluristem Therapeutics Surging Following Receipt Of Orphan Drug ...  Benzinga
Pluristem Therapeutics (PSTI) Stock Surges on FDA Orphan Drug Designation  TheStreet.com
Maxim Group Keeps Pluristem Therapeutics Inc (NASDAQ:PSTI) As Buy; Has Price ...
New York: In an analyst report issued to clients and investors on Tuesday morning, Maxim Group maintained their Buy rating on shares of Pluristem Therapeutics Inc (NASDAQ:PSTI). They currently have a $3.00 target price on the firm. Maxim Group's target ...